NCT00149851View on ClinicalTrials.gov

A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)

PHASE2CompletedINTERVENTIONAL
Enrollment

832

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Symptomatic Gastroespohageal Reflux Disease
Interventions
DRUG

Tegaserod

Trial Locations (1)

07936-108

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00149851 - A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD) | Biotech Hunter | Biotech Hunter